Immature ovarian teratoma

Summary

Immature ovarian teratoma (MONDO:0018369) is a disease and 4 clinical trials. Top therapeutic interventions include bleomycin sulfate, cisplatin, and palbociclib. A subtype of malignant teratoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Clinical trials: 4

Clinical features

Epidemiology

Prevalence records

23 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000	0.07	Europe	Validated
Annual incidence	<1 / 1 000 000	0.051	Austria	Validated
Annual incidence	<1 / 1 000 000	0.052	Belgium	Validated
Annual incidence	<1 / 1 000 000	0.043	Bulgaria	Validated
Annual incidence	<1 / 1 000 000	0.056	Croatia	Validated
Annual incidence	<1 / 1 000 000	0.034	Czech Republic	Validated
Annual incidence	<1 / 1 000 000	0.074	Estonia	Validated
Annual incidence	<1 / 1 000 000	0.053	Finland	Validated
Annual incidence	<1 / 1 000 000	0.042	Germany	Validated
Annual incidence	<1 / 1 000 000	0.052	Ireland	Validated
Annual incidence	<1 / 1 000 000	0.039	Italy	Validated
Annual incidence	<1 / 1 000 000	0.027	Latvia	Validated
Annual incidence	<1 / 1 000 000	0.017	Lithuania	Validated
Annual incidence	<1 / 1 000 000	0.031	Malta	Validated
Annual incidence	<1 / 1 000 000	0.084	Norway	Validated
Annual incidence	<1 / 1 000 000	0.048	Poland	Validated
Annual incidence	<1 / 1 000 000	0.045	Portugal	Validated
Annual incidence	<1 / 1 000 000	0.045	Slovakia	Validated
Annual incidence	<1 / 1 000 000	0.075	Slovenia	Validated
Annual incidence	<1 / 1 000 000	0.063	Spain	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	immature ovarian teratoma
Mondo ID	MONDO:0018369
Orphanet	398987
DOID	DOID:6331
ICD-11	551209361
NCIT	C39995, C8111
SNOMED CT	254871000
UMLS	C0346182
MedGen	138044
GARD	0021654
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	no

Also known as: immature germ cell teratoma of ovary · immature germ cell teratoma of the ovary · immature ovarian teratoma · immature teratoma · immature teratoma of ovary · immature teratoma of the ovary · malignant germ cell teratoma of ovary · malignant germ cell teratoma of the ovary · malignant ovarian germ cell teratoma · malignant ovarian teratoma · malignant teratoma of ovary · malignant teratoma of the ovary · ovarian germ cell immature teratoma · ovarian immature germ cell teratoma · ovarian immature teratoma · ovarian malignant teratoma · ovary malignant teratoma

Data availability: 5 cell lines.

Disease family

This is a subtype of malignant teratoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › nongerminomatous germ cell tumor › teratoma › malignant teratoma › immature ovarian teratoma

Related subtypes (6): pineal region immature teratoma, immature gastric teratoma, intermediate malignant teratoma, malignant teratoma of testis, malignant teratoma of mediastinum, immature extragonadal teratoma

Subtypes (2): malignant struma ovarii, childhood immature teratoma of ovary

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03067181	PHASE3	RECRUITING	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT04684368	PHASE2	RECRUITING	A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT01037790	PHASE2	COMPLETED	Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
NCT00060372	PHASE1	COMPLETED	Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BLEOMYCIN SULFATE	4	1
CISPLATIN	4	1
PALBOCICLIB	4	1